Oruka Insider Sells $463K in Stock as Shares Skyrocket 650%, but Here's What Matters for Investors [Globe and Mail, The (Toronto, Canada)]
Oruka Therapeutics, Inc. (ORKA)
Company Research
Source: Globe and Mail, The
This transaction represented 17% of Joana Goncalves's direct Common Stock holdings, reducing her direct position from 40,377 to 33,377 shares. The sale involved direct ownership only and stemmed from the exercise of 3,500 options immediately prior to sale, with no indirect participation. Goncalves retains Employee Stock Options (right to buy): 211,063 shares (direct) and Employee Warrants (right to buy): 182,492 shares (direct), which can be converted to Common Stock. Joana Goncalves, Chief Medical Officer at Oruka Therapeutics (NASDAQ:ORKA) , reported the sale of 7,000 shares of Common Stock for a transaction value of approximately $463,000 on April 15, 2026, according to an SEC Form 4 filing Transaction summary Metric Value Shares sold (direct) Transaction value Post-transaction shares (direct) Post-transaction value (direct ownership) $2.19 million Transaction value based on SEC Form 4 weighted average purchase price ($66.12); post-transaction value based o
Show less
Read more
Impact Snapshot
Event Time:
ORKA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ORKA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ORKA alerts
High impacting Oruka Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ORKA
News
- Oruka Insider Sells $463K in Stock as Shares Skyrocket 650%, but Here's What Matters for Investors [Yahoo! Finance]Yahoo! Finance
- Oruka Therapeutics price target raised to $85 from $45 at Wedbush [Yahoo! Finance]Yahoo! Finance
- Oruka Therapeutics (ORKA) had its price target raised by Wedbush from $45.00 to $85.00. They now have an "outperform" rating on the stock.MarketBeat
- Oruka Therapeutics (ORKA) had its "buy" rating reaffirmed by Guggenheim. They now have a $125.00 price target on the stock.MarketBeat
- Oruka Therapeutics (ORKA) had its price target raised by BTIG Research from $73.00 to $78.00. They now have a "buy" rating on the stock.MarketBeat
ORKA
Earnings
- 3/12/26 - Beat
ORKA
Sec Filings
- 4/21/26 - Form 424B7
- 4/17/26 - Form ARS
- 4/17/26 - Form DEFA14A
- ORKA's page on the SEC website